lifesciences.knect365.com/east-west-ceo/speakers/guo-liang-yu

Dr. Guo-Liang Yu is the global CEO of Apollomics Pharmaceuticals Inc (CBT Pharmaceuticals), an innovative therapeutics company devoted to curing cancer by ...

www.linkedin.com/in/tim-clackson-8579b96

President of Research and Development, Chief Scientific Officer. ARIAD Pharmaceuticals, Inc. December 1994 – May 2017 22 years 6 months. Cambridge, MA.

www.linkedin.com/in/meera-tugnait-4a134b4

Senior Director Clinical Pharmacology at Blueprint Medicines. Cambridge, Massachusetts. Biotechnology. Blueprint Medicines · ARIAD Pharmaceuticals, Inc.

media.nature.com/original/nature-assets/nbt/journal/v30/n3/extref/nbt.2146-S1.xls

516, 5733748, Yu; Guo-Liang|Rosen; Craig, Human Genome Sciences, Inc. ...... on Behalf of the University of Arizona|Fred Hutchinson Cancer Research Center ...... Lynne|Zoller; Mark|Pawson; Anthony, Ariad Pharmaceuticals, Inc. Human syk ...... derivative or a derivative of a furin analogue and a heterologous sequence.

pubs.rsc.org/en/content/articlelanding/2014/md/c4md00048j

Compound, Company, ALK activity, Other targets, Clinical states, References ..... is a 2,6-diaminopyrimidine derivative TKI developed by Ariad Pharmaceuticals, ..... K. Rikova , A. Guo , Q. Zeng , A. Possemato , J. Yu , H. Haack , J. Nardone , K. ... S. J. Meech , L. McGavran , L. F. Odom , X. Liang , L. Meltesen , J. Gump , Q.

aasldpubs.onlinelibrary.wiley.com/doi/pdf/10.1002/hep.28212

The following authors have nothing to disclose: Matthew J. Vitalone, Liang Wei, .... Teng-Yu Lee1, Yi-Ju Chen1, Jaw-Town Lin2, Hsiu-Jon Ho2, Ming-Shi- ...... Shuichi Kaneko - Grant/Research Support: MDS, Co., Inc, Chugai Pharma., Co., ...... Lewis R. Roberts - Grant/Research Support: Bristol Myers Squibb, ARIAD Phar-.

escholarship.umassmed.edu/cgi/viewcontent.cgi?article=1872&context=gsbs_diss

Nov 8, 2016 ... Commons, Pharmacology Commons, and the Therapeutics Commons ..... Data in chapter III is submitted as “Ma L, Pak M, Ou J, Yu J, Yi S, Zhu LJ, ..... that a 2- phenylaminopyrimindin derivative, CGP57-148B, now widely ... Ponatinib is derived from AP23464, one of Ariad's dual ABL/SRC inhibitor, and is.

www.lls.org/annual-report/2017

Oct 27, 2017 ... education, and tirelessly advocating on behalf of patients. ..... Pharmaceuticals, Inc. (Celator) through which LLS provided funding of approximately $4,100 to Celator .... tracts, and other derivative products. ..... Qiming Liang, PhD, 2016 .... Dr. Jianhua Yu is funded in part by ..... ARIAD Pharmaceuticals, Inc.

pubs.acs.org/doi/full/10.1021/np5000796?src=recsys

Feb 5, 2014 ... Natural Products Branch, Developmental Therapeutics Program, ...... Another rapamycin derivative showing promise in the treatment of ..... (240) A further discussion of the problems by Livermore on behalf of the ... (Future Science Ltd.) ...... Yu-E Yu , Rong Sheng , Jian-Xia Mo , Min Huang , Liang Ouyang ...